Media headlines about Ekso Bionics (NASDAQ:EKSO) have been trending somewhat negative on Thursday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ekso Bionics earned a coverage optimism score of -0.03 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.3682406433782 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Separately, Zacks Investment Research upgraded Ekso Bionics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th.
Shares of Ekso Bionics stock opened at $1.57 on Thursday. The company has a quick ratio of 3.48, a current ratio of 3.81 and a debt-to-equity ratio of 0.23. Ekso Bionics has a 1-year low of $0.99 and a 1-year high of $4.77. The firm has a market capitalization of $90.93, a P/E ratio of -1.69 and a beta of -0.59.
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.